This company has been marked as potentially delisted and may not be actively trading. Cyclo Therapeutics (CYTH) Institutional Ownership Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclo Therapeutics (NASDAQ:CYTH)CurrentInstitutional OwnershipPercentage68.55%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$25.10KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$75.90K Get CYTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYTH Institutional Buying and Selling by Quarter Cyclo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Two Sigma Securities LLC42,541$25K0.0%N/A0.148% 2/7/2025EPIQ Capital Group LLC689,447$407K0.1%-6.8%2.396% 8/10/2024EPIQ Capital Group LLC817,270$1.04M0.4%-4.3%2.856% 2/15/2024Founders Fund V Management LLC480,708$764K80.8%N/A2.115% 2/15/2024Founders Fund VI Management LLC110,023$175K1.4%N/A0.484% 11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204% 8/16/2021State Street Corp44,700$457K0.0%N/A0.703% 8/13/2021Geode Capital Management LLC42,577$435K0.0%+133.2%0.670% 8/13/2021Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383% 5/12/2021Geode Capital Management LLC18,257$149K0.0%N/A0.287% (Data available from 1/1/2016 forward) CYTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYTH shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclo Therapeutics shares: Founders Fund V Management LLC ($764K), EPIQ Capital Group LLC ($407K), and Founders Fund VI Management LLC ($175K), Two Sigma Securities LLC ($25K).Learn more on Cyclo Therapeutics' institutional investors. What percentage of Cyclo Therapeutics' stock is owned by institutional investors? 68.55% of Cyclo Therapeutics' stock is owned by institutional investors. Learn more on CYTH's institutional investor holdings. Which institutional investors have been buying Cyclo Therapeutics' stock? The following institutional investors have purchased Cyclo Therapeutics' stock in the last 24 months: Founders Fund V Management LLC ($480.71K), Founders Fund VI Management LLC ($110.02K), and Two Sigma Securities LLC ($42.54K). How much institutional buying is happening at Cyclo Therapeutics? Institutional investors have bought a total of 42,541 shares in the last 24 months. This purchase volume represents approximately $25.10K in transactions. Which of Cyclo Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Cyclo Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($86.52K). How much institutional selling is happening at Cyclo Therapeutics? Institutional investors have sold a total of 86,524 shares in the last 24 months. This volume of shares sold represents approximately $75.90K in transactions. Related Companies XBIT Major Shareholders BYSI Major Shareholders ELUT Major Shareholders IOBT Major Shareholders ADAG Major Shareholders ZNTL Major Shareholders CHRS Major Shareholders OCX Major Shareholders CRBP Major Shareholders ABVC Major Shareholders This page (NASDAQ:CYTH) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTH Stock Alerts